Emergent Biosolutions (NYSE:EBS) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Emergent Biosolutions Inc. (NYSE:EBS) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.85 and traded as high as $12.05. Emergent Biosolutions shares last traded at $11.3350, with a volume of 566,824 shares.

Analysts Set New Price Targets

EBS has been the subject of several recent analyst reports. Wall Street Zen raised Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 30th. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research report on Friday, October 24th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Trading Down 4.7%

The company has a fifty day simple moving average of $11.97 and a 200-day simple moving average of $9.87. The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14. The stock has a market cap of $595.31 million, a price-to-earnings ratio of 8.72 and a beta of 2.30.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Wednesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $1.18. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The company had revenue of $231.10 million for the quarter, compared to the consensus estimate of $203.67 million. On average, research analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the completion of the sale, the director owned 98,417 shares in the company, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EBS. Millennium Management LLC raised its holdings in Emergent Biosolutions by 68.9% in the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after acquiring an additional 1,020,582 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after purchasing an additional 121,583 shares during the period. Public Employees Retirement System of Ohio raised its stake in shares of Emergent Biosolutions by 135.9% in the second quarter. Public Employees Retirement System of Ohio now owns 13,181 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 7,593 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Emergent Biosolutions in the second quarter valued at $68,000. Finally, PFG Investments LLC bought a new position in Emergent Biosolutions in the second quarter worth $73,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.